AI assistant
Sending…
Spyre Therapeutics, Inc. — Director's Dealing 2021
Feb 26, 2021
32226_dirs_2021-02-25_30b2e3eb-c88b-4fa3-a555-fd366838d3a7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2021-02-23
Reporting Person: Brownstein Sara (Director)
More from Spyre Therapeutics, Inc.
Regulatory Filings
2026
Jun 1
Declaration of Voting Results & Voting Rights Announcements
2026
May 29
Regulatory Filings
2026
May 5
Interim / Quarterly Report
2026
May 5
Regulatory Filings
2026
Apr 16
Capital/Financing Update
2026
Apr 13
Regulatory Filings
2026
Apr 13
Regulatory Filings
2026
Apr 13
Proxy Solicitation & Information Statement
2026
Apr 10
Major Shareholding Notification
2026
Mar 27